New drug combo shows promise in shrinking cervical tumors before surgery
NCT ID NCT07205497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the immunotherapy drug QL1706 to standard chemotherapy before hysterectomy can improve outcomes for people with locally advanced cervical cancer. About 54 participants will receive three cycles of the combination, then surgery if the tumor shrinks enough. Researchers will measure how many patients have no cancer left after treatment and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and tuvonralimab (QL1706) combined with cisplatin and albumin-bound paclitaxel
- What this could lead to
- If this works, it could offer a more effective treatment option for locally advanced cervical cancer, potentially improving survival and reducing the need for more extensive surgery.
- What could go wrong
- This is an early phase 2 trial with only 54 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and it is not yet proven to be better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sun Yat-sen Memorial Hospital of the Sun Yat-sen University
Guangzhou, Guangdong, 537216, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could vitamin d predict cervical cancer treatment success?
- Can a triple-threat approach wipe out cervical cancer before surgery?
- Particle beam and immune therapy join forces against cervical cancer
- Dual immunotherapy plus chemo may shrink cervical tumors before surgery
- Protein clues may predict cervical cancer return
- Could a 3-Week radiation course beat the standard 5-Week for cervical cancer?